Anti-angiogenic effects of thioridazine involving the FAK-mTOR pathway

Microvascular Research

Volumn 84, Issue 3, 2012, Pages 227-234

  Byun, Hyun Jung ^a   Lee, Jeong Heon ^b   Kim, Boh Ram ^a   Kang, Sokbom ^a   Dong, Seung Myung ^a   Park, Mi Sun ^a   Lee, Seung Hoon ^c   Park, Sung Ho ^d   Rho, Seung Bae ^a  

^a National Cancer Center   (South Korea)

^b Chonbuk National University Medical School   (South Korea)

^c Yongin University   (South Korea)

^d Hallym University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHAVBETA5 INTEGRIN; FOCAL ADHESION KINASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE B; RAPAMYCIN; S6 KINASE; THIORIDAZINE; VASCULOTROPIN; WORTMANNIN;

ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL ADHESION; CELL FUNCTION; CELL INVASION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; METASTASIS INHIBITION; MIGRATION INHIBITION; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; TUMOR VASCULARIZATION; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FOCAL ADHESION PROTEIN-TYROSINE KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTEGRIN ALPHAVBETA3; NEOPLASM INVASIVENESS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; SIGNAL TRANSDUCTION; THIORIDAZINE; TOR SERINE-THREONINE KINASES;

MAMMALIA;

EID: 84868087634     PISSN: 00262862     EISSN: 10959319     Source Type: Journal    
DOI: 10.1016/j.mvr.2012.09.006     Document Type: Article

References (56)

1. Akiyama S., et al. Circumvention of multiple-drug resistance in human cancer cells by thioridazine, trifluoperazine, and chlorpromazine. J. Natl. Cancer Inst. 1986, 76:839-844.
2. Arbiser J.L., et al. Solenopsin, the alkaloidal component of the fire ant (Solenopsis invicta), is a naturally occurring inhibitor of phosphatidylinositol-3-kinase signaling and angiogenesis. Blood 2007, 109:560-565.
3. Barczyk M., et al. Integrins. Cell Tissue Res. 2010, 339:269-280.
4. Campbell N.E., et al. Extracellular matrix proteins and tumor angiogenesis. J. Oncol. 2010, 2010:586905.
5. Cance W.G., et al. Immunohistochemical analyses of focal adhesion kinase expression in benign and malignant human breast and colon tissues: correlation with preinvasive and invasive phenotypes. Clin. Cancer Res. 2000, 6:2417-2423.
6. Cowap J., Hardy J. Thioridazine in the management of cancer-related sweating. J. Pain Symptom Manage. 1998, 15:266.
7. Duronio V., et al. Downstream signalling events regulated by phosphatidylinositol 3-kinase activity. Cell. Signal. 1998, 10:233-239.
8. Eliceiri B.P., Cheresh D.A. The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J. Clin. Invest. 1999, 103:1227-1230.
9. Engbring J.A., Kleinman H.K. The basement membrane matrix in malignancy. J. Pathol. 2003, 200:465-470.
10. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat. Rev. Cancer 2002, 2:795-803.
11. Folkman J., Shing Y. Angiogenesis. J. Biol. Chem. 1992, 267:10931-10934.
12. Franch H.A., et al. Phosphatidylinositol 3-kinase activity is required for epidermal growth factor to suppress proteolysis. J. Am. Soc. Nephrol. 2002, 13:903-909.
13. Fruman D.A., et al. Hypoglycaemia, liver necrosis and perinatal death in mice lacking all isoforms of phosphoinositide 3-kinase p85 alpha. Nat. Genet. 2000, 26:379-382.
14. Glass-Marmor L., et al. Calmodulin antagonists decrease glucose 1,6-bisphosphate, fructose 1,6-bisphosphate, ATP and viability of melanoma cells. Eur. J. Pharmacol. 1996, 313:265-271.
15. Hynes R.O. Integrins: bidirectional, allosteric signaling machines. Cell 2002, 110:673-687.
16. Jiang B.H., Liu L.Z. AKT signaling in regulating angiogenesis. Curr. Cancer Drug Targets 2008, 8:19-26.
17. Jiang B.H., et al. Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:1749-1753.
18. Jiang X., et al. Differential FAK phosphorylation at Ser-910, Ser-843 and Tyr-397 induced by angiotensin II, LPA and EGF in intestinal epithelial cells. Cell. Signal. 2007, 19:1000-1010.
19. Judson P.L., et al. Overexpression of focal adhesion kinase, a protein tyrosine kinase, in ovarian carcinoma. Cancer 1999, 86:1551-1556.
20. 3H]azidopine photolabeling of P-glycoprotein by newly synthesized dihydropyridine analogues in a human cell line. Cancer Res. 1989, 49:3190-3195.
21. Kandel E.S., Hay N. The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp. Cell Res. 1999, 253:210-229.
22. Kanner S.B., et al. Monoclonal antibodies to individual tyrosine-phosphorylated protein substrates of oncogene-encoded tyrosine kinases. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:3328-3332.
23. Knable M. Thioridazine for elderly patients with dementia. West. J. Med. 1999, 171:22.
24. Kuphal S., et al. Integrin signaling in malignant melanoma. Cancer Metastasis Rev. 2005, 24:195-222.
25. Lechertier T., Hodivala-Dilke K. Focal adhesion kinase and tumour angiogenesis. J. Pathol. 2012, 226:404-412.
26. Lee O.H., et al. Sphingosine 1-phosphate induces angiogenesis: its angiogenic action and signaling mechanism in human umbilical vein endothelial cells. Biochem. Biophys. Res. Commun. 1999, 264:743-750.
27. Li C.H., et al. Benzo[a]pyrene inhibits angiogenic factors-induced alphavbeta3 integrin expression, neovasculogenesis, and angiogenesis in human umbilical vein endothelial cells. Toxicol. Sci. 2010, 118:544-553.
28. Lightfoot H.M., et al. Upregulation of focal adhesion kinase (FAK) expression in ductal carcinoma in situ (DCIS) is an early event in breast tumorigenesis. Breast Cancer Res. Treat. 2004, 88:109-116.
29. Ly K.L., et al. Depression in palliative care: a systematic review. Part 2. Treatment. Palliat. Med. 2002, 16:279-284.
30. Ma A., et al. Serine phosphorylation of focal adhesion kinase in interphase and mitosis: a possible role in modulating binding to p130(Cas). Mol. Biol. Cell 2001, 12:1-12.
31. Meng Q., et al. Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway. Cell. Signal. 2006, 18:2262-2271.
32. Mitra S.K., Schlaepfer D.D. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr. Opin. Cell Biol. 2006, 18:516-523.
33. Mitra S.K., et al. Focal adhesion kinase: in command and control of cell motility. Nat. Rev. Mol. Cell Biol. 2005, 6:56-68.
34. Mitra S.K., et al. Intrinsic FAK activity and Y925 phosphorylation facilitate an angiogenic switch in tumors. Oncogene 2006, 25:5969-5984.
35. Munyon W.H., et al. Cytotoxic effects of neuroleptic drugs. Psychopharmacology (Berl) 1987, 91:182-188.
36. Ocak S., et al. DNA copy number aberrations in small-cell lung cancer reveal activation of the focal adhesion pathway. Oncogene 2010, 29:6331-6342.
37. Owens L.V., et al. Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors. Cancer Res. 1995, 55:2752-2755.
38. Owens L.V., et al. Focal adhesion kinase as a marker of invasive potential in differentiated human thyroid cancer. Ann. Surg. Oncol. 1996, 3:100-105.
39. Pantazaki A.A., Lialiaris T.S. A combined biochemical and cytogenetic study of thioridazine-induced damage to nucleic acids. Mutagenesis 1999, 14:243-248.
40. Patarroyo M., et al. Laminin isoforms in tumor invasion, angiogenesis and metastasis. Semin. Cancer Biol. 2002, 12:197-207.
41. Plate K.H., et al. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992, 359:845-848.
42. Playford M.P., Schaller M.D. The interplay between Src and integrins in normal and tumor biology. Oncogene 2004, 23:7928-7946.
43. Ramu A., et al. Restoration of doxorubicin responsiveness in doxorubicin-resistant P388 murine leukaemia cells. Br. J. Cancer 1984, 50:501-507.
44. Rho S.B., et al. A gene signature-based approach identifies thioridazine as an inhibitor of phosphatidylinositol-3'-kinase (PI3K)/AKT pathway in ovarian cancer cells. Gynecol. Oncol. 2011, 120:121-127.
45. Rho S.B., et al. Programmed cell death 6 (PDCD6) inhibits angiogenesis through PI3K/mTOR/p70S6K pathway by interacting of VEGFR-2. Cell. Signal. 2012, 24:131-139.
46. Risau W. Mechanisms of angiogenesis. Nature 1997, 386:671-674.
47. Sood A.K., et al. Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion. Am. J. Pathol. 2004, 165:1087-1095.
48. Sottile J. Regulation of angiogenesis by extracellular matrix. Biochim. Biophys. Acta 2004, 1654:13-22.
49. Strobl J.S., et al. Inhibition of human breast cancer cell proliferation in tissue culture by the neuroleptic agents pimozide and thioridazine. Cancer Res. 1990, 50:5399-5405.
50. Weis S.M., Cheresh D.A. αv Integrins in angiogenesis and cancer. Cold Spring Harb. Perspect. Med. 2011, 1:a006478.
51. Xia C., et al. Regulation of angiogenesis and tumor growth by p110 alpha and AKT1 via VEGF expression. J. Cell. Physiol. 2006, 209:56-66.
52. Yom C.K., et al. Clinical significance of high focal adhesion kinase gene copy number and overexpression in invasive breast cancer. Breast Cancer Res. Treat. 2011, 128:647-655.
53. Yoshiji H., et al. Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res. 1996, 56:2013-2016.
54. Zachary I., Rozengurt E. Focal adhesion kinase (p125FAK): a point of convergence in the action of neuropeptides, integrins, and oncogenes. Cell 1992, 71:891-894.
55. Zhao X., Guan J.L. Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis. Adv. Drug Deliv. Rev. 2011, 63:610-615.
56. Zhukovsky D.S. Fever and sweats in the patient with advanced cancer. Hematol. Oncol. Clin. North. Am. 2002, 16:579-588.